Novavax (NVAX) executive compensation, 2026 proxy

John C. Jacobs, President and CEO, was paid $8.9M in 2025, up 74% from $5.1M the year before. The CEO-to-median-employee pay ratio was 52:1.

Filed
April 27, 2026
Annual meeting
June 18, 2026
Pay year
2025
Named executives
6
CEO total pay
$8.9M+74% vs prior year
CEO to median employee
52:1
CEO pay in equity
83%$7.3M in awards
Prior say-on-pay support
72%of votes cast
Total Revenue
$1.1B2025 total revenue
Cash Position
$857MAs of December 31, 2025
Say-on-Pay Support
72.3%Prior year vote

How Jacobs was paid

$8.9M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary9%Stock awards40%Option awards42%Non-equity incentive7%All other compensation1%

Named executive officers

ExecutiveTotal
John C. JacobsPresident and CEO$8,856,015
James P. KellyEVP, Chief Financial Officer and Treasurer$2,986,228
Elaine O'HaraEVP, Chief Strategy Officer$3,688,276
Mark J. Casey, J.D.EVP, Chief Legal Officer and Corporate Secretary$2,810,453
John J. TrizzinoFormer President and Chief Operating Officer$1,709,950
Ruxandra Draghia-Akli, M.D., Ph.D.Former EVP, Head of Research & Development$2,303,380

What changed and why

  • $8.9MCEO total compensation increased to $8,856,015 in 2025 from $5,087,461 in 2024.
  • $1.1BTotal revenue reached $1.1B in 2025 alongside significant strategic milestones.
  • 72.3%Say-on-pay received 72.3% support from votes cast at the prior meeting.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.